_______________________________________________________________________________________________________________
What does it mean to be a true industry pioneer? For world-leading viral vector specialist, OXB, such pioneership is defined by relentless innovation and groundbreaking impact. Founded in 1995 and spun out from Oxford University, England, OXB’ s mission was clear: to develop products that leveraged its extensive expertise in its Lentiviral vector platform –“ to make cell and gene therapy a universally accessible clinical option” for all. Driven by passion, tenacity, and scientific excellence, OXB had soon surpassed this vision, treating the first ever patient in-vivo with a lentiviral vector – a landmark breakthrough that revolutionized the biomedical industry forever.
Following that triumph, OXB remained at the forefront of industry excellence. When the pandemic struck in 2020, the company seized the opportunity to partner with AstraZeneca for large-scale commercial manufacture of the Covid-19 vaccine, subsequently producing over 100 million doses. This success further strengthened OXB’ s reputation as a leading expert in viral vector development and manufacturing, and, two years later, saw it transform into an international organization. The company soon acquired a site in Bedford, Massachusetts, to focus on AAV development, and then an additional two sites in Lyon and Strasbourg, France. Not only did these global facilities augment OXB’ s global presence, but also expanded its expertise in other viral vectors, further driving its goal to be vectoragnostic in supporting all its clients’ needs, from its established LentiVector TM Platform to its InAAVate TM( AAV) Platform and beyond.
As a result, the company made a strategic shift from being a development company to operating as a full CDMO and, in turn, rebranded from its original name – Oxford
40